Connect with us

Business

AstraZeneca and Oxford defend Covid vaccine trials after questions raised in the U.S. – CNBC

“We believe that this product will never be licensed in the U.S.,” one group of critical U.S.-based analysts wrote this week.

Published

on

post featured image
ADVERTISEMENT

AstraZeneca’s building in Luton, Britain.
AstraZeneca and the University of Oxford are defending the results and methods used in their phase three vaccine trials on the back of criticism from experts in the U.S., stressing the “highest standards” were used and that “additional analysis will be conducted.” 
AstraZeneca shares are down by around 6% this week after questions were raised over its vaccine candidate, for which the company said combined results revealed it to be 70% effective. The figure…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

post featured image
AMC says bankruptcy is off the table after raising more than $900 million since December – CNBC
post featured image
Tesla accuses engineer of stealing Warp Drive secrets – Engadget
Rebranded ‘NewsNation’ moving Joe Donlon to solo news hour at 6 pm – Robert Feder